BR112015028748A2 - Composições de vacina compreendendo oligonucleotídeos imunoestimulantes - Google Patents

Composições de vacina compreendendo oligonucleotídeos imunoestimulantes

Info

Publication number
BR112015028748A2
BR112015028748A2 BR112015028748A BR112015028748A BR112015028748A2 BR 112015028748 A2 BR112015028748 A2 BR 112015028748A2 BR 112015028748 A BR112015028748 A BR 112015028748A BR 112015028748 A BR112015028748 A BR 112015028748A BR 112015028748 A2 BR112015028748 A2 BR 112015028748A2
Authority
BR
Brazil
Prior art keywords
immunostimulant
oligonucleotides
antigen
vaccine compositions
component
Prior art date
Application number
BR112015028748A
Other languages
English (en)
Inventor
Joseph Dominowski Paul
K Rai Sharath
Mary Sly Laurel
Patrick Cook Corey
Mwangi Duncan
L Foss Dennis
Lee Krebs Richard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112015028748A2 publication Critical patent/BR112015028748A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES DE VACINA COMPREENDENDO OLIGONUCLEOTÍDEOS IMUNOESTIMULANTES. A invenção proporciona uma composição de vacina compreendendo um componente antígeno e um componente adjuvante, sendo que o componente adjuvante compreende um oligonucleotídeo imunoestimulante de classe P e tanto uma combinação de uma saponina e um esterol; quanto de uma fase oleosa compreendendo um óleo e, opcionalmente, um ou mais emulsificantes, tal fase oleosa compreendendo 2-20% v/v da composição de vacina, sendo que o componente antígeno é um antígeno de EHV ou um antígeno de Leishmania.
BR112015028748A 2013-05-14 2014-05-12 Composições de vacina compreendendo oligonucleotídeos imunoestimulantes BR112015028748A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823189P 2013-05-14 2013-05-14
PCT/US2014/037705 WO2014186291A1 (en) 2013-05-14 2014-05-12 Novel vaccine compositions comprising immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
BR112015028748A2 true BR112015028748A2 (pt) 2017-09-19

Family

ID=50897961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028748A BR112015028748A2 (pt) 2013-05-14 2014-05-12 Composições de vacina compreendendo oligonucleotídeos imunoestimulantes

Country Status (20)

Country Link
EP (2) EP2996719B1 (pt)
JP (2) JP6505084B2 (pt)
CN (2) CN108079290A (pt)
AR (1) AR096277A1 (pt)
AU (2) AU2014265649B2 (pt)
BR (1) BR112015028748A2 (pt)
CA (2) CA2911938C (pt)
DK (1) DK3542819T3 (pt)
ES (2) ES2894138T3 (pt)
HK (1) HK1219426A1 (pt)
HR (1) HRP20211452T1 (pt)
HU (1) HUE056040T2 (pt)
LT (1) LT3542819T (pt)
MX (2) MX367268B (pt)
PL (1) PL3542819T3 (pt)
PT (2) PT2996719T (pt)
RU (1) RU2627447C2 (pt)
SI (1) SI3542819T1 (pt)
WO (1) WO2014186291A1 (pt)
ZA (1) ZA201507774B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
ES2878475T3 (es) * 2015-07-20 2021-11-18 Zoetis Services Llc Composiciones adyuvantes liposomales
BE1023538B1 (fr) * 2016-04-22 2017-04-26 Sil'innov Scrl Silices mésoporeuses et leur procédé de synthèse
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7904021A (nl) * 1979-05-22 1980-04-29 Gist Brocades Nv Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen.
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
PL212212B1 (pl) * 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
SG167667A1 (en) * 2002-07-03 2011-01-28 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
KR101151202B1 (ko) * 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES
ES2859673T3 (es) * 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis

Also Published As

Publication number Publication date
JP6505084B2 (ja) 2019-04-24
EP2996719B1 (en) 2019-06-26
HUE056040T2 (hu) 2022-01-28
PL3542819T3 (pl) 2022-01-10
WO2014186291A1 (en) 2014-11-20
AU2017232231A1 (en) 2017-10-12
ES2894138T3 (es) 2022-02-11
MX2019009407A (es) 2019-09-26
DK3542819T3 (da) 2021-09-20
RU2627447C2 (ru) 2017-08-08
AR096277A1 (es) 2015-12-16
SI3542819T1 (sl) 2021-11-30
NZ713360A (en) 2021-06-25
MX2015015758A (es) 2016-03-16
CN108079290A (zh) 2018-05-29
CA2911938A1 (en) 2014-11-20
MX367268B (es) 2019-08-12
LT3542819T (lt) 2021-11-10
CN105263518B (zh) 2018-03-20
EP2996719A1 (en) 2016-03-23
CN105263518A (zh) 2016-01-20
ZA201507774B (en) 2017-09-27
EP3542819B1 (en) 2021-08-18
JP2016518446A (ja) 2016-06-23
RU2015146752A (ru) 2017-06-20
HRP20211452T1 (hr) 2021-12-24
ES2742325T3 (es) 2020-02-13
JP2019108328A (ja) 2019-07-04
PT2996719T (pt) 2019-09-03
HK1219426A1 (zh) 2017-04-07
PT3542819T (pt) 2021-10-14
AU2014265649A1 (en) 2015-11-12
CA2911938C (en) 2019-07-16
EP3542819A1 (en) 2019-09-25
AU2014265649B2 (en) 2017-10-19
CA3027289A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
CY1120934T1 (el) Νευροδραστικα στεροειδη και μεθοδοι χρησης αυτων
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018069220A2 (pt) uso de polipeptídeo que tem atividade de dnase para tratamento de tecidos
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
EP3261668A4 (en) Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
BR112017017217A2 (pt) ?composição que compreende ramnolipídeo e siloxano?
BR112018008103A2 (pt) análogos de celastrol
BR112017009277A2 (pt) compostos de silicone
CL2018001192A1 (es) Análogos de saponina triterpeno
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
BR112015028748A2 (pt) Composições de vacina compreendendo oligonucleotídeos imunoestimulantes
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
BR112017002061A2 (pt) composições e regimes para tratamento bucal
BR112018015819A2 (pt) regulação da expressão gênica por bloqueio de poliadenilação mediado por aptâmero
ES2722926T3 (es) Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]